<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493880</url>
  </required_header>
  <id_info>
    <org_study_id>INdex</org_study_id>
    <nct_id>NCT03493880</nct_id>
  </id_info>
  <brief_title>The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments</brief_title>
  <official_title>The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on multiple studies, the immune (systemic inflammation) and nutrition index were
      correlated with short- and long-term prognosis for gastric cancer. With the increasing
      application of preoperative treatments (chemotherapy and chemoradiotherapy), the issues
      concerning how are the immuno-nutrition index be altered under the effects of perioperative
      treatments and what are the clinical values of these index should be clarified.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immune (systemic inflammation) index includes:

      NLR (Neutrophil-to-Lymphocyte Ratio); PLR (Platelet-to-Lymphocyte Ratio); SII (Systemic
      Immune-Inflammation Index); GPS (Glasgow Prognostic Score); mGPS (modified Glasgow Prognostic
      Score); PI (Prognostic Index);

      The nutrition index includes:

      NRS2002; PNI (Prognostic Nutrition Index);
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Anticipated">September 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Pathological response</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Pathological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-years overall survival</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>3-years overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-years disease-free survival</measure>
    <time_frame>Three years after surgery</time_frame>
    <description>3-years disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative morbidity</measure>
    <time_frame>One month after surgery</time_frame>
    <description>Postoperative morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>yp TNM Stage</measure>
    <time_frame>One month after surgery</time_frame>
    <description>yp TNM Stage</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Neoadjuvant Chemoradiotherapy</condition>
  <condition>Systemic Inflammatory Response Syndrome (SIRS)</condition>
  <condition>Nutrition Aspect of Cancer</condition>
  <arm_group>
    <arm_group_label>naCT</arm_group_label>
    <description>Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naCRT</arm_group_label>
    <description>Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients with advanced gastric cancer or esophagogastric cancer receiving
        neoadjuvant chemotherapy or chemoradiotherapy will be included for this observational
        study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma

          -  Received neoadjuvant (preoperative) chemotherapy or chemoradiotherapy

          -  Diagnosed clinical advanced gastric cancer or esophagogastric cancer

        Exclusion Criteria:

          -  Lack of immuno-nutrition data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuangxi Li, M.D., Ph.D.</last_name>
    <email>lishx@hsc.pku.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuangxi Li, M.D.</last_name>
      <email>lishx@hsc.pku.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jiafu Ji, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziyu Li, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuangxi Li, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shuang-xi Li</investigator_full_name>
    <investigator_title>Associate Chief Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

